Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI
Kairos Pharma (NYSE American: KAPA) will present at the LD Micro Invitational XVI at the Luxe Sunset Boulevard Hotel in Los Angeles on Monday, May 18, 2026 at 1:00 PM PDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kairos Pharma (NYSE American: KAPA) will present at the LD Micro Invitational XVI at the Luxe Sunset Boulevard Hotel in Los Angeles on Monday, May 18, 2026 at 1:00 PM PDT. CEO and Chairman Dr. John Yu will provide an update on the company’s clinical program and partnering activities.
The LD Micro Invitational XVI runs May 18–19, 2026, featuring micro and small-cap companies presenting in half-hour slots and meeting investors. A webcast link is indicated for Kairos Pharma’s presentation.
Details
News Market Reaction – KAPA
On May 13, the day this news came out, KAPA closed 4.33% below the previous close.
Data tracked by StockTitan Argus for the May 13 session.
Key Figures
- Shelf registration size
- $75,000,000
- S-3 filed Jan 12, 2026
- ATM program size
- $4,524,949
- At-the-market equity program under S-3
- Net loss
- $4.1 million
- Nine months ended Sep 30, 2025
- Net loss
- $2.6 million
- Full year 2024
- Shares outstanding
- 21,411,198
- Record date May 15, 2026 for Annual Meeting
- Reverse split range
- 1:3 to 1:250
- Proposed in 2026 PRE 14A
- Equity plan increase
- 5,000,000 shares
- Proposed 2023 Equity Incentive Plan amendment
- Registered for resale
- 6,425,000 shares
- 424B3 prospectus supplement dated Apr 1, 2026
Historical Context
-
Auditor highlights going-concern language in recent 10-K financial statements.
-
Company recognized for ENV‑105-based resistance-modulating oncology approach.
-
Binding deal for CL-273 pan‑EGFR inhibitor expanding NSCLC pipeline.
-
Term sheet to acquire two NSCLC assets CL‑273 and CL‑741 from Celyn.
-
Investor conference presentation and one-on-one meeting availability announcement.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Los Angeles, California--(Newsfile Corp. - May 13, 2026) - Kairos Pharma, Ltd. (NYSE American: KAPA) announced today that it will be participating in the 16th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Los Angeles, CA May 18th and 19th, 2026.
Kairos Pharma, Ltd. is scheduled to present on Monday, May 18, 2026 at 01:00 PM. John Yu CEO, will be presenting on behalf of the company.
Dr. John Yu, CEO and Chairman of Kairos Pharma will give an update on Kairos' clinical program and partnering activities.
Event: LD Micro Invitational XVI
Date: Monday, May 18, 2026
Time: 01:00 PM PDT
WEBCAST LINK
Summary of LD Micro Invitational XVI
- The 2026 LD Micro Invitational XVI will take place May 18th and 19th, 2026 at the Luxe Hotel Sunset Boulevard Hotel in Los Angeles.
- Registration will begin at 5:30 PM PT on May 17th in conjunction with a welcome reception.
- Presentations will take place from 9:00 AM PT - 5:00 PM PT on the 18th, followed by panels and keynote speakers.
- Presentations will take place from 9:00 AM PT - 5:00 PM PT on the 19th, followed by the LD Micro Moneyball Afterparty.
This two-day event will feature micro and small-cap companies across all sectors, presenting in half-hour increments, and attending private meetings with investors.
About Kairos Pharma, Ltd.
Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105-a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer aimed at addressing significant unmet medical needs. For more information, visit kairospharma.com.
About LD Micro
LD Micro, a wholly owned subsidiary of Freedom US Markets, was founded in 2006 with the sole purpose of being an independent resource in the micro-cap space. Through its dynamic, investor-driven conferences and curated company exposure, LD has served as an invaluable asset to all those interested in discovering the next generation of great companies. For more information on LD Micro, visit www.ldmicro.com.
To register, please contact: registration@ldmicro.com.
For further information on Kairos Pharma, Ltd. :
CoreIR
3102486693
investors@kairospharma.com
kairospharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.